View Older Stories View More Recent Stories
-
Roth Capital Starts Sierra Metals Inc. (SMTS) at Buy
-
Digital Turbine (APPS): PT Jumps To $2.50 After CEO Meeting at Roth
-
AGS Commences Initial Public Offering
-
FuelCell Energy (FCEL): F4Q17 Strong on Korean Project - Roth
-
Quantenna to Present at Upcoming Investor Conferences
-
ADOMANI Completes $11 Million Secondary Equity Offering; Boustead Securities Underwrites and Places First Form S-1 Fundraise for a NASDAQ-Listed Regulation A+ IPO Issuer
-
ADOMANI Completes $11 Million Secondary Equity Offering; Boustead Securities Underwrites and Places First Form S-1 Fundraise for a NASDAQ-Listed Regulation A+ IPO Issuer
-
ADOMANI, Inc. Announces Closing of Public Offering of Units
-
IMAX Corporation (IMAX) PT Lowered to $25.50 at Roth Capital
-
Adomani (ADOM) Prices Best Efforts Public Offering of 3.67M Units at $3.00/Unit
-
ADOMANI, Inc. Announces Pricing of Public Offering of Units
-
Roth Capital Downgrades Ohr Pharmaceutical (OHRP) to Neutral Following MAKO Results
-
Roth Capital Starts Semtech Corp. (SMTC) at Buy, Sees Upside to Street Expectations
-
Roth Capital Starts Sequans Communications (SQNS) at Buy
-
Roth Capital Starts Fitbit (FIT) at Buy, 'Fitness Pioneer with Legitimate Digital Therapeutic Aspirations'
-
Ladenburg Thalmann Appoints Michael J. Higgins as Managing Director, Equity Research Covering Healthcare
-
UPDATE: Roth Capital Resumes Apollo Endosurgery (APEN) at Buy
-
MassRoots to Present at Upcoming Cannabis and Blockchain Technology Conferences
-
Radisys Closes $17 Million Senior Notes Financing to Support Software-Systems Business Strategy
-
Galectin Therapeutics (GALT) PT Raised to $8 at Roth Capital
-
ROTH Capital Partners Expands Technology Practice with Addition of Scott Searle, CFA, Managing Director, Senior Research Analyst and transition of Brian Alger, CFA to Managing Director, Investment Ban
-
Roth Capital Resumes Flex Pharma (FLKS) at Buy
-
Roth Capital Assumes Pixelworks (PXLW) at Buy
-
Roth Capital Resumes Juniper Pharmaceuticals (JNP) at Buy
-
Pretium Resources (PVG): Permit for Throughput Increase Bigger than Anticipated - Roth Capital
-
Roth Capital Starts Piedmont Lithium Limited (PLLLY) at Neutral, 'Emerging U.S. Lithium Play'
-
Roth Capital Assumes MaxLinear (MXL) at Buy
-
Delcath Announces Exit from Convertible Note
-
Revolution Lighting Technologies (RVLT) PT Lowered to $5 at Roth Capital
-
SenesTech (SNES) PT Lowered to $3.75 at Roth Capital Following 3Q
-
Pre-Open Movers 12/28: (LIVE) (DRAD) (EROS) Higher; (RVLT) (EKSO) (MEET) Lower (more...)
-
UPDATE: Energous Corp (WATT) PT Raised to $45.80 at Roth Capital, Street High, 'FCC Certifies Mid Field Transmitter'
-
Air Industries (AIRI) PT Raised to $2 at Roth Capital Following 3Q
-
iClick Interactive Announces IPO Underwriters' Exercise of Over-Allotment Option
-
Roth Capital Reiterates Buy on Galmed Pharma (GLMD)
-
My Size Announces Closing of $2.5 Million Public Offering of Common Stock and Warrants
-
Roth Capital Reiterates Buy on Ohr Pharmaceutical (OHRP) Ahead of MAKO Results
-
iPicĀ® Entertainment To List On Nasdaq for Initial Public Offering via JOBS Act Regulation A+
-
iClick Interactive Asia Group Limited (ICLK) IPO Opens 6% Higher
-
iClick Interactive Asia Group Limited (ICLK) Prices 3.75M Share IPO at $8/Sh
-
iClick Interactive Announces Pricing of Initial Public Offering
-
UPDATE: First Solar (FSLR) Has More Upside & Positive Sentiment Ahead - Roth
-
Attunity Ltd. Announces Closing of Option Relating to Public Offering of Ordinary Shares
-
My Size (MYSZ) Prices 3.83M Shares Common Offering at $0.851/Sh
-
My Size Announces Pricing of $2.5 Million Public Offering of Common Stock and Warrants
-
Roth Capital Starts Moleculin Biotech (MBRX) at Buy, 'liposomal anthracycline Annamycin sits in a goldilocks zone'
-
Yingli Green Energy (YGE) PT Lowered to $1.60 at Roth Capital on 3Q Report; 'Weak Margins Drive Large Q3 Write-Down'
-
ReneSola Ltd. (SOL) PT Raised to $2.80 at Roth Capital on 3Q Report; 'Healthy 3Q Highlights Improved Earnings Power Post Spin-Off'
-
Madrigal Pharma (MDGL) Prices 1.5M Share Common Offering at $83/Sh
-
Madrigal Pharmaceuticals Prices Public Offering of Common Stock

